These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 21143705)

  • 1. Midbrain serotonin transporters in de novo and L-DOPA-treated patients with early Parkinson's disease--a [123 I]-ADAM SPECT study.
    Beucke JC; Plotkin M; Winter C; Endrass T; Amthauer H; Juckel G; Kupsch A
    Eur J Neurol; 2011 May; 18(5):750-5. PubMed ID: 21143705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias.
    Cheshire P; Ayton S; Bertram KL; Ling H; Li A; McLean C; Halliday GM; O'Sullivan SS; Revesz T; Finkelstein DI; Storey E; Williams DR
    Mov Disord; 2015 May; 30(6):796-804. PubMed ID: 25649148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preserved serotonin transporter binding in de novo Parkinson's disease: negative correlation with the dopamine transporter.
    Strecker K; Wegner F; Hesse S; Becker GA; Patt M; Meyer PM; Lobsien D; Schwarz J; Sabri O
    J Neurol; 2011 Jan; 258(1):19-26. PubMed ID: 20644949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline [(123) I]FP-CIT SPECT (DaTSCAN) severity correlates with medication use at 3 years in Parkinson's disease.
    Nissen T; Malek N; Grosset KA; Newman EJ; Patterson J; Hadley D; Grosset DG
    Acta Neurol Scand; 2014 Mar; 129(3):204-8. PubMed ID: 23962145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia.
    Jeon BS; Jeong JM; Park SS; Kim JM; Chang YS; Song HC; Kim KM; Yoon KY; Lee MC; Lee SB
    Ann Neurol; 1998 Jun; 43(6):792-800. PubMed ID: 9629849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [[123I]beta-CIT SPECT imaging of dopamine and serotonin transporters in Parkinson's disease and multiple system atrophy.
    Berding G; Brücke T; Odin P; Brooks DJ; Kolbe H; Gielow P; Harke H; Knoop BO; Dengler R; Knapp WH
    Nuklearmedizin; 2003 Feb; 42(1):31-8. PubMed ID: 12601452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical correlates of raphe serotonergic dysfunction in early Parkinson's disease.
    Qamhawi Z; Towey D; Shah B; Pagano G; Seibyl J; Marek K; Borghammer P; Brooks DJ; Pavese N
    Brain; 2015 Oct; 138(Pt 10):2964-73. PubMed ID: 26209314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonin transporters in the midbrain of Parkinson's disease patients: a study with 123I-beta-CIT SPECT.
    Kim SE; Choi JY; Choe YS; Choi Y; Lee WY
    J Nucl Med; 2003 Jun; 44(6):870-6. PubMed ID: 12791812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease.
    Kish SJ; Tong J; Hornykiewicz O; Rajput A; Chang LJ; Guttman M; Furukawa Y
    Brain; 2008 Jan; 131(Pt 1):120-31. PubMed ID: 17956909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.
    Antonini A; Schwarz J; Oertel WH; Pogarell O; Leenders KL
    Mov Disord; 1997 Jan; 12(1):33-8. PubMed ID: 8990051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single photon emission computed tomography striatal asymmetry index may predict dopaminergic responsiveness in Parkinson disease.
    Contrafatto D; Mostile G; Nicoletti A; Raciti L; Luca A; Dibilio V; Lanzafame S; Distefano A; Drago F; Zappia M
    Clin Neuropharmacol; 2011; 34(2):71-3. PubMed ID: 21406999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substantia nigra echogenicity: A structural correlate of functional impairment of the dopaminergic striatal projection in Parkinson's disease.
    Weise D; Lorenz R; Schliesser M; Schirbel A; Reiners K; Classen J
    Mov Disord; 2009 Aug; 24(11):1669-75. PubMed ID: 19514075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced midbrain serotonin transporter availability in drug-naïve patients with depression measured by SERT-specific [(123)I] nor-beta-CIT SPECT imaging.
    Joensuu M; Tolmunen T; Saarinen PI; Tiihonen J; Kuikka J; Ahola P; Vanninen R; Lehtonen J
    Psychiatry Res; 2007 Feb; 154(2):125-31. PubMed ID: 17289353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levodopa induces long-lasting modification in the functional activity of the nigrostriatal pathway.
    Riverol M; Ordóñez C; Collantes M; DiCaudo C; Peñuelas I; Arbizu J; Marcilla I; Luquin MR
    Neurobiol Dis; 2014 Feb; 62():250-9. PubMed ID: 24076099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study.
    Iranzo A; Valldeoriola F; Lomeña F; Molinuevo JL; Serradell M; Salamero M; Cot A; Ros D; Pavía J; Santamaria J; Tolosa E
    Lancet Neurol; 2011 Sep; 10(9):797-805. PubMed ID: 21802993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levodopa and the progression of Parkinson's disease.
    Fahn S; Oakes D; Shoulson I; Kieburtz K; Rudolph A; Lang A; Olanow CW; Tanner C; Marek K;
    N Engl J Med; 2004 Dec; 351(24):2498-508. PubMed ID: 15590952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing dopaminergic function in Parkinson's disease: levodopa kinetic-dynamic modeling and SPECT.
    Contin M; Martinelli P; Riva R; Dondi M; Fanti S; Pettinato C; Scaglione C; Albani F; Baruzzi A
    J Neurol; 2003 Dec; 250(12):1475-81. PubMed ID: 14673582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism.
    Lorberboym M; Djaldetti R; Melamed E; Sadeh M; Lampl Y
    J Nucl Med; 2004 Oct; 45(10):1688-93. PubMed ID: 15471834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it?
    Pirker W
    Mov Disord; 2003 Oct; 18 Suppl 7():S43-51. PubMed ID: 14531046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in nigro-striatal impairment in clinical variants of early Parkinson's disease: evidence from a FP-CIT SPECT study.
    Rossi C; Frosini D; Volterrani D; De Feo P; Unti E; Nicoletti V; Kiferle L; Bonuccelli U; Ceravolo R
    Eur J Neurol; 2010 Apr; 17(4):626-30. PubMed ID: 20050904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.